I agree lots of “ calm before the storm”Looking at the news flow history, there has been little change of news since the very positive update being October 4th. They, then announced for the first time ever in writing the discussion of accelerated approval. Since then, on this BB. There has been ample chatter of the meaning, process & implications of accelerated approval. Today, notable pointed out, the long known opportunity Onc has been granted under its relationship with CGAR: They can use historical placebo evidence. Opportunities.? Easier to get & keep enrolment patients.*** Obviously less cost & less time. Prior to the October 4th, N.R. On Sept 19th , they updated on the Bracelet results indicating favourable results including the overlooked FACT that more than 1/2 the Pela patients were still alive. Then again for the first time in Onc history, they provided forward looking sales numbers for Pela for MBc only at $2.5 billion/ year Then at the Q3 update, they put that number forward, & stated this will be what we are presenting to potential collaborators. Roche for example has a P/ E ratio of 19. +/- a few points, depending on dates. Even using an extremely low P/ E number for ONClets say, 2 for example. Would put a buyout price of $5 billion. After-all, Im reasonable calculations, they need to invest lots of time & money, to get to that $2.5 billion in sales. Using Roche existing P/ E would equate to a significant $47 billion. Granted, Sales are not all net up income. Pharma margins are large, They dont generally disclose individual product costs. Proprietary & business competitive reasons. Lets go real low & assume 10% bottom line from top number sales. Still equates to $4.7 billion. Company worth. At present number of shares, the math works out to about $12 PS/ billion. The analysts consensus of buy with average price of $5ps, is extremely conservative & does not discuss a buyout. Food for thought. Onc , must have a significant $$$ deal, before staring the MBc trial. The panc trial is being handled under the CGAR umbrella, with little $$$ being discussed. Watch for upcoming news. There has to be something & soon! Even a fire sale lowball of $1billion , would make many happy. However, all of my calcs only consider the MBc sales. Add on the pancreatic cancer sales, other Gobblet potentials, Onc is worth significantly more than the fire sale price. Like I said, & some have trouble with , the trading price of Onc , or any company that matter, has little to do with its real corporate value. Markets & share prices move all over the place , every day, hour, minute. Want to buy a business. First question? What is the business value of the in place or future income. And specifically for Roche, what can Pela do for their existing drug markets. We know , Pela can incresse market potential significantly, by increasing the opportunities of qualified patients. ( Turing cold tumours hot). Anyhow, great week ahead all.